

# Michael Soyka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2391677/publications.pdf>

Version: 2024-02-01

85  
papers

4,005  
citations

159585

30  
h-index

128289

60  
g-index

89  
all docs

89  
docs citations

89  
times ranked

5643  
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. <i>Nature Genetics</i> , 2015, 47, 1443-1448.	21.4	435
2	Diagnosis and Pharmacotherapy of Alcohol Use Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 815.	7.4	382
3	Treatment of Benzodiazepine Dependence. <i>New England Journal of Medicine</i> , 2017, 376, 1147-1157.	27.0	256
4	Substance misuse, psychiatric disorder and violent and disturbed behaviour. <i>British Journal of Psychiatry</i> , 2000, 176, 345-350.	2.8	236
5	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010, , CD004332.	2.8	232
6	Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 641-53.	2.1	135
7	Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 317-324.	1.4	114
8	Neurobiology of Aggression and Violence in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 913-920.	4.3	105
9	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
10	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. <i>Behavior Genetics</i> , 2016, 46, 151-169.	2.1	98
11	Genome-wide association study identifies inversion in the <i>CTRB1-CTRB2</i> locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. <i>Gut</i> , 2018, 67, 1855-1863.	12.1	97
12	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1987-1999.	1.8	96
13	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 160-187.	2.6	88
14	Pharmacotherapy of alcoholism – an update on approved and off-label medications. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1187-1199.	1.8	81
15	Cognitive Functioning During Methadone and Buprenorphine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 699-703.	1.4	69
16	Alcohol Use Disorders in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Treatment. <i>European Addiction Research</i> , 2015, 21, 78-87.	2.4	63
17	Less Impairment on One Portion of a Driving-Relevant Psychomotor Battery in Buprenorphine-Maintained Than in Methadone-Maintained Patients. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 490-493.	1.4	59
18	One-year Mortality Rates of Patients Receiving Methadone and Buprenorphine Maintenance Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 657-660.	1.4	55

#	ARTICLE	IF	CITATIONS
19	Genome-wide Association Study and Meta-analysis on Alcohol-associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	7.3	54
20	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020, 159, 1276-1289.e7.	1.3	53
21	Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?. <i>Pharmacopsychiatry</i> , 2018, 51, 243-250.	3.3	50
22	Psychopathology in dual diagnosis and non-addicted schizophrenics - are there differences?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 232-238.	3.2	49
23	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005, 39, 101-108.	3.1	45
24	New developments in the management of opioid dependence: focus on sublingual buprenorphine&ndash;naloxone. <i>Substance Abuse and Rehabilitation</i> , 2015, 6, 1.	4.8	41
25	Baclofen for alcohol use disorder. <i>The Cochrane Library</i> , 2018, 2018, CD012557.	2.8	37
26	Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 619-626.	1.8	36
27	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. <i>Journal of Hepatology</i> , 2014, 61, 1073-1079.	3.7	35
28	Delinquency and criminal offenses in former schizophrenic inpatients 7?12 years following discharge. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 289-94.	3.2	34
29	Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies. <i>European Psychiatry</i> , 2019, 59, 15-24.	0.2	34
30	Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective. <i>American Journal on Addictions</i> , 2003, 12, s69-s80.	1.4	33
31	A Comparison of Cognitive Function in Patients under Maintenance Treatment with Heroin, Methadone, or Buprenorphine and Healthy Controls: An Open Pilot Study. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 497-508.	2.1	33
32	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 148-161.	4.8	33
33	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	3.7	33
34	Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. <i>Psychopharmacology</i> , 2018, 235, 3451-3464.	3.1	31
35	Flupenthixol in Relapse Prevention in Schizophrenics with Comorbid Alcoholism: Results from an Open Clinical Study. <i>European Addiction Research</i> , 2003, 9, 65-72.	2.4	30
36	Nalmefene for the treatment of alcohol dependence: a current update. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 675-684.	2.1	30

#	ARTICLE	IF	CITATIONS
37	Relapse Prevention in Alcoholism. <i>CNS Drugs</i> , 1997, 7, 313-327.	5.9	28
38	Use of Acamprosate and Different Kinds of Psychosocial Support in Relapse Prevention of Alcoholism. <i>Drugs in R and D</i> , 2002, 3, 1-12.	2.2	28
39	Pain management in opioid maintenance treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1993-2005.	1.8	27
40	Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. <i>Neuropsychopharmacology</i> , 2019, 44, 660-667.	5.4	26
41	Prevalence of Delusional Jealousy in Psychiatric Disorders*. <i>Journal of Forensic Sciences</i> , 2011, 56, 450-452.	1.6	25
42	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021, 116, 106-115.	0.4	25
43	Criminal Behavior in Opioid-Dependent Patients Before and During Maintenance Therapy: 6-Year Follow-Up of a Nationally Representative Cohort Sample. <i>Journal of Forensic Sciences</i> , 2012, 57, 1524-1530.	1.6	24
44	A combination of carbamazepine/tiapride in outpatient alcohol detoxification. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 197-200.	3.2	23
45	Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 395-401.	3.2	23
46	Methamphetamine withdrawal and the restoration of cognitive functions – a study over a course of 6 months abstinence. <i>Psychiatry Research</i> , 2019, 281, 112599.	3.3	21
47	Dual Diagnosis in Patients with Schizophrenia. <i>CNS Drugs</i> , 1996, 5, 414-425.	5.9	20
48	PET and SPECT Findings in Alcohol Hallucinosi: Case Report and Super-Brief Review of the Pathophysiology of this Syndrome. <i>World Journal of Biological Psychiatry</i> , 2000, 1, 215-218.	2.6	20
49	Outpatient Alcohol Detoxification: Implementation Efficacy and Outcome Effectiveness of a Model Project. <i>European Addiction Research</i> , 2004, 10, 180-187.	2.4	20
50	Thalamic hypofunction in alcohol hallucinosi: FDG PET findings. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 259-262.	1.8	20
51	Cognitive function in short- and long-term substitution treatment: Are there differences?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 400-408.	2.6	20
52	Why should addiction medicine be an attractive field for young physicians?. <i>Addiction</i> , 2009, 104, 169-172.	3.3	19
53	Buprenorphine Use in Pregnant Opioid Users: A Critical Review. <i>CNS Drugs</i> , 2013, 27, 653-662.	5.9	19
54	L-dopa abuse in a patient with former alcoholism. <i>Addiction</i> , 1992, 87, 117-118.	3.3	18

#	ARTICLE	IF	CITATIONS
55	Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: Clinical results from an open study. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 217-224.	2.6	16
56	Val158Met COMT polymorphism and risk of aggression in alcohol dependence. <i>Addiction Biology</i> , 2015, 20, 197-204.	2.6	14
57	Treatment of opioid dependence with buprenorphine: current update. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 299-308.	3.7	14
58	XRCC5 as a Risk Gene for Alcohol Dependence: Evidence from a Genome-Wide Gene-Set-Based Analysis and Follow-up Studies in Drosophila and Humans. <i>Neuropsychopharmacology</i> , 2015, 40, 361-371.	5.4	12
59	Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 1409-1417.	5.0	10
60	The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals. <i>European Addiction Research</i> , 2018, 24, 255-265.	2.4	10
61	Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Othersâ€”A Perspective of German Addiction Medicine Experts. <i>Frontiers in Psychiatry</i> , 2020, 11, 592199.	2.6	10
62	Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study. <i>American Journal on Addictions</i> , 2014, 23, 563-569.	1.4	9
63	Serotonin and Dopamine Candidate Gene Variants and Alcohol- and Non-Alcohol-Related Aggression. <i>Alcohol and Alcoholism</i> , 2015, 50, 690-699.	1.6	9
64	Buprenorphine and Buprenorphine/Naloxone Intoxication in Children â€” How Strong is the Risk?. <i>Current Drug Abuse Reviews</i> , 2013, 6, 63-70.	3.4	8
65	Delusional jealousy in psychiatric disorders of later life. <i>International Journal of Geriatric Psychiatry</i> , 1992, 7, 539-542.	2.7	7
66	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 168-174.	2.4	7
67	TO SUBSTITUTE OR NOT SUBSTITUTEâ€”OPTIMAL TACTICS FOR THE MANAGEMENT OF BENZODIAZEPINE DEPENDENCE. <i>Addiction</i> , 2010, 105, 1876-1877.	3.3	7
68	Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patientsâ€”A Critical Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 718811.	3.5	7
69	Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers. <i>Frontiers in Psychiatry</i> , 2021, 12, 771126.	2.6	7
70	Short-term changes in global methylation and hydroxymethylation during alcohol detoxification. <i>European Neuropsychopharmacology</i> , 2019, 29, 897-903.	0.7	6
71	A genetic variant in tollâ€”like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021, 41, 2139-2148.	3.9	6
72	Propofol dependency. <i>Addiction</i> , 1997, 92, 1369-1370.	3.3	5

#	ARTICLE	IF	CITATIONS
73	Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. <i>CNS Drugs</i> , 2019, 33, 649-657.	5.9	5
74	Buprenorphineâ€“naloxone buccal soluble film for the treatment of opioid dependence: current update. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 339-347.	5.0	4
75	Abstinence or maintenance treatment in substance use disorders?. <i>Addiction</i> , 2016, 111, 775-776.	3.3	4
76	Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting â€“ a case series. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 599-604.	2.1	4
77	Pharmacological trials in alcoholics-some comments on methodological problems. <i>Addiction</i> , 1997, 92, 956-958.	3.3	3
78	Commentary on <sc>H</sc>ser <i>etâ€“al</i>. (2014): To retain or not to retainâ€“open questions in opioid maintenance therapy. <i>Addiction</i> , 2014, 109, 88-89.	3.3	3
79	Recent advances in the treatment of opioid use disordersâ€“focus on long-acting buprenorphine formulations. <i>World Journal of Psychiatry</i> , 2021, 11, 543-552.	2.7	3
80	Colocalization analysis of pancreas eQTLs with risk loci from alcoholic and novel non-alcoholic chronic pancreatitis GWAS suggests potential disease causing mechanisms. <i>Pancreatology</i> , 2022, 22, 449-456.	1.1	3
81	Substance abuse in schizophrenics. <i>British Journal of Psychiatry</i> , 1994, 165, 836-837.	2.8	0
82	Pathophysiological mechanisms possibly involved in the development of alcohol hallucinosis. <i>Addiction</i> , 1995, 90, 289-290.	3.3	0
83	Pharmacotherapies of Opioid Detoxificationâ€“ An Evaluation of Different Pharmacotherapeutical Strategies. <i>Alcoholism Treatment Quarterly</i> , 1999, 17, 47-53.	0.8	0
84	FURTHER REFLECTIONS ON â€“WHY SHOULD ADDICTION MEDICINE BE AN ATTRACTIVE FIELD FOR YOUNG PHYSICIANS?â€™. <i>Addiction</i> , 2009, 104, 177-178.	3.3	0
85	Pharmacotherapy of Alcohol Use Disorders. , 2020, , 1-17.		0